June 2023 | Media
News & Announcements
June 2023 | Statement
June 26, 2023 – Last Friday, the Biden Administration issued an executive order on “Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services” . The executive order includes an explicit directive to the Secretaries of the Treasury, Labor and HHS...
June 2023 | Statement
Cambridge, MA, June 23, 2023 – On June 24, 2022, The US Supreme Court released a final decision on Dobbs v. Jackson Women’s Health Organization , which eliminated constitutional protections of the right to abortion care established by Roe v. Wade in 1973. While the protections granted...
June 2023 | Statement
May 2023 | Blog
May 2023 | Statement
May 10, 2023 – Today, in a landmark step for reproductive health, a joint FDA advisory committee voted unanimously to allow a birth control pill to be offered over the counter (OTC). The advisory committee vote reflects the decades of science showing that birth control pills are safe and...
April 2023 | Statement
Cambridge, MA, April 10, 2023 – On Friday, April 7, 2023, a judge in a Texas federal court released a ruling in Alliance for Hippocratic Medicine v. FDA. The ruling places a stay on the FDA’s approval of mifepristone and seeks to remove it from the market nationwide. The same day...
March 2023 | Media
March 2023 | Statement
Insights from the World Population Review indicate that over 13 million children are born to women who are under 20 years old. Disturbingly, more than 90% of these births (about 12 million) occur in developing countries, with African countries topping the list. To address high rates of teenage...
March 2023 | Statement
Ibis Reproductive Health South Africa is proud to announce its partnership with Advocates For Youth (AFY) as the new Sub-Saharan Africa regional lead for the AMAZE Africa initiative, with the intention of amplifying ongoing efforts in the region to make comprehensive sexuality education resources...
March 2023 | Statement
The FDA announced today that an advisory committee meeting is scheduled for May 9 and 10 to review the first-ever application for an over-the-counter birth control pill. In July 2022, HRA Pharma announced it had submitted this application to the FDA to switch Opill, a progestin-only, daily birth...